BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Evercore ISI
August 6, 2024 5:02 AM EDTEvercore ISI analyst Cory Kasimov raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $115.00 (from $113.00) while maintaining a Outperform rating.
The analyst comments "BMRN printed an encouraging 2Q beat-and-raise w/ solid progress for Voxzogo and long-awaited strategic direction not to mention... More
